Q-omics provides the consensus-scored API5P2 profile across patient tissues and cancer cell-line models. API5P2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, API5P2 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, API5P2 RNA expression shows 8,719 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight MESO, THCA, and CCRCC as cancer lineages where API5P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for API5P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes API5P2 survival associations across molecular data types. API5P2 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible API5P2 RNA expression–survival associations across cancer types. High API5P2 expression shows unfavorable associations in ACC, LUAD, DLBC, SKCM and BRCA, but favorable associations in MESO. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .025). Together, the overview and detailed table identify MESO as the clearest survival context for API5P2 RNA expression.
This table summarizes API5P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for API5P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. API5P2 shows lower tumor expression in THCA and KICH and higher tumor expression in BRCA, COAD, LUSC and LUAD. The THCA box plot shows higher API5P2 RNA expression in normal versus tumor tissue (log2 FC = −0.082, t-test p < 0.001).
This table shows molecular features associated with API5P2 in patient tissues and cancer cell lines. In patient samples, API5P2 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
